Ibogaine vs Ayahuasca: What the Evidence Says

Ibogaine vs ayahuasca: they are two different plant-derived substances with different chemistry and, in the reviews we read, different main medical concerns. Ayahuasca is a brew made from two Amazonian plants and is used mostly in spiritual or ceremonial settings. Ibogaine is an alkaloid from the root of a West African shrub and is studied mainly for substance use disorders. Peer-reviewed reviews we read on 30 October 2026 describe limited evidence for both: the ibogaine reviews report apparent benefit for withdrawal and craving from mostly small or uncontrolled studies alongside a documented cardiac risk, and the ayahuasca reviews report good tolerability in few, small controlled studies. The legal comparison is closer than the question suggests. In US federal regulation, ibogaine and DMT, a compound in ayahuasca, are both Schedule I, and a Supreme Court ruling about one church's use of an ayahuasca-type tea is not a general exception. In Mexico's Ley General de Salud DMT is listed, while neither ibogaine nor ayahuasca is named. This page compares them without recommending either. It is general information, not medical or legal advice.

The comparison at a glance

The two timing rows measure different things. A blood half-life describes how long a metabolite stays in the blood. It does not say how long an experience lasts, so the table does not set one against the other.

Where each comes from and what is in it

Ibogaine comes from the root of Tabernanthe iboga, a shrub found in the rainforests of West Africa, according to a 2023 systematic review of ibogaine for substance use disorders. A systematic review of clinical trials notes that the effects of iboga alkaloids differ from those of classic hallucinogens such as LSD, mescaline and psilocybin.

Ayahuasca is traditionally used by Indigenous groups in northwestern Amazonian countries. A 2024 review in CNS Spectrums describes it as brewed from the leaves of Psychotria viridis, which supply DMT, and the stalks of Banisteriopsis caapi, which supply beta-carbolines such as harmine.

How each is used and what the sources say about timing

A review of ayahuasca's history and pharmacology describes it as used in spiritual and religious contexts, including by churches such as Santo Daime, Barquinha and União do Vegetal. It reports that nausea and vomiting are the most common purgative effects, seen in 62 percent of respondents in one survey, and that vomiting is traditionally seen as expelling toxins and traumas. It cites one study of freeze-dried ayahuasca in which the experience lasted 4 to 6 hours. The same review says accounts range from enthusiastic testimonials to reports of serious physical and psychological harm.

Ibogaine has been studied mainly as a possible treatment for substance use disorders. The 2023 review above says its metabolite noribogaine has a long half-life in the blood of about 28 to 49 hours. That is a measure of the metabolite in blood, not of how long a person feels the effects, and none of the sources we read gave a single figure for the length of an ibogaine experience. The same review tabulates a double-blind placebo-controlled study whose recorded adverse events include visual hallucinations during the 72 hours after exposure, which is an observation window and not a session length. A review of setting factors says ibogaine is often used without medical supervision.

What the reviews say about risk

For ibogaine, a 2026 review in Addiction describes a rare yet clinically significant cardiotoxic risk, with QTc prolongation and potentially fatal ventricular arrhythmias. Its abstract says case reports show these events occur with therapeutic doses of ibogaine and in individuals without pre-existing cardiac conditions, and it notes large person-to-person differences in how the liver enzyme CYP2D6 processes ibogaine. It says future ibogaine-assisted treatment should be conducted exclusively under controlled medical supervision, with CYP2D6 genotyping and rigorous monitoring of cardiovascular functioning. An updated systematic review of adverse events found that acute events within 24 hours were mainly cardiac, with QTc prolongation the most common, and warns that most reports are case reports, so cause cannot be firmly established. The review of setting factors concludes that controlled settings with trained staff and equipment for medical, psychiatric and cardiac monitoring are essential. The 2023 review reports that most deaths it examined occurred in a home or clandestine setting.

For ayahuasca, the CNS Spectrums review says human experimental and naturalistic studies suggest good safety and tolerability, while noting that controlled studies are few, small, mostly single-dose and short in follow-up. A systematic review of 78 articles on adverse events found ayahuasca and DMT generally safe, with some adverse events reported in humans, and said serious adverse effects are rarely reported within healthy populations, indicating an acceptable safety profile for the traditional use of ayahuasca and DMT in controlled settings. The same review reports that animal studies using higher doses of ayahuasca have shown abortifacient and teratogenic effects, and that harmala alkaloids show potential toxicity at higher doses, which may increase when combined with certain medications; harmaline raised the most concerns in preclinical models. The authors caution that findings from high-dose studies of synthetic compounds may not apply directly to the therapeutic doses of plant extracts. Pregnancy is therefore a question for a physician, as is any medication. We did not source which medications interact with ayahuasca, so this page gives no list. These findings do not apply to every person or every setting, and they do not mean ayahuasca is risk-free.

What the evidence for benefit looks like

The two sets of reviews say different things, and none compares the substances head to head. A systematic review of clinical trials of 24 studies covering 705 people who received ibogaine or noribogaine concluded that the published data suggest ibogaine is an effective therapeutic intervention for substance use disorders, reducing withdrawal symptoms and craving, with possible benefit for depressive and trauma-related symptoms. Only two of those studies were randomized, double-blind, controlled trials, most of the rest were open-label or observational, and the review reports severe medical complications and deaths that seem associated with neuro- and cardiotoxic effects and calls for rigorous, medically supervised study designs. The 2023 systematic review concluded that the results show some efficacy of ibogaine for substance use disorders but that its cardiotoxicity and mortality are of concern.

For ayahuasca, the CNS Spectrums review reports that human studies suggest good tolerability, often with reduced depressive and anxiety symptoms, while its controlled studies are few and small. A narrative review of ayahuasca, ibogaine and kratom for opioid withdrawal and use disorder says the evidence for all three is mostly small observational or animal studies and calls for high-quality longitudinal research. None of these reviews tests either substance as a treatment against the other, so the page cannot say which, if either, works better.

Legal status

In the United States, 21 CFR 1308.11 lists both ibogaine (code 7260) and dimethyltryptamine (DMT, code 7435) among Schedule I hallucinogenic substances. It does not name ayahuasca or its plants, and this page does not say how the listing applies to a brew. In Gonzales v. O Centro Espírita Beneficente União do Vegetal (2006), the Supreme Court held that the government had not shown, at the preliminary injunction stage, a compelling interest in barring a church's sacramental use of a DMT-containing tea under the Religious Freedom Restoration Act, and said that DMT's Schedule I classification did not by itself settle the question. That decision concerned one church and does not make ayahuasca generally lawful.

In Mexico, the consolidated Ley General de Salud (text through reforms published on 15 January 2026) lists DMT in group I of Article 245. We searched the whole text and found no mention of ibogaine, iboga, ayahuasca or the plants used to make it. That is not a statement that either is permitted. We did not read other official lists or regulator rules, and we state nothing about any clinic or ceremony.

How this page was made

We read each source named here on 30 October 2026, and reopened the review abstracts, the Mosca and Ruffell full texts and the legal sources again on 31 October 2026 while revising. Reviews were read as PubMed abstracts and, where noted in our source ledger, in part as full text, and none was independently checked by a clinician. We did not contact any provider. Laws change, so confirm current rules. Talk with a qualified physician about your own health, including any heart condition, pregnancy or medication you take, before considering either substance.